| Identification | Back Directory | [Name]
PLX8394 | [CAS]
1393466-87-9 | [Synonyms]
PLX8394
PLX8394;PLX-8394;PLX 8394
1-Pyrrolidinesulfonamide, N-[3-[[5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-3-fluoro-, (3R)- | [Molecular Formula]
C25H21F3N6O3S | [MDL Number]
MFCD29472263 | [MOL File]
1393466-87-9.mol | [Molecular Weight]
542.53 |
| Chemical Properties | Back Directory | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 39 mg/mL (71.89 mM);Water : < 0.1 mg/mL (insoluble) | [form ]
Solid | [pka]
6.33±0.40(Predicted) | [color ]
White to light yellow | [InChIKey]
YYACLQUDUDXAPA-MRXNPFEDSA-N | [SMILES]
N1(S(NC2=CC=C(F)C(C(C3C4=CC(C5=CN=C(C6CC6)N=C5)=CN=C4NC=3)=O)=C2F)(=O)=O)CC[C@@H](F)C1 |
| Hazard Information | Back Directory | [Uses]
Combination therapies comprising KRAS G12C inhibitors and Raf kinase inhibitors for treating KRAS G12C cancers.BRAF inhibitor. |
|
|